Robinson Pharma Expands Costa Mesa, California, Operations
09/17/2019
According to company officials, this new addition brings Robinson Pharma to now six buildings and totaling over 650,000 square feet. The new state-of-the-art eco-friendly facility will serve as RPI’s newest expansion to accommodate its continuing business growth.
The building spans 100,276 square feet and sits on more than five acres of land. RPI has committed to invest $20M in this facility to better serve its customers with the latest advances in nutraceutical contract manufacturing and quality assurance.
With these new investments, RPI said it will keep pace with the growing demand for wellness products and continue in its vision to provide the best in service in the supplement industry.
Robinson Pharma, Inc., is a Southern California-based full-service contract manufacturer of dietary supplements with over 650,000 square feet of production capabilities of capsules, softgels, tablets, powders, and liquids. Robinson Pharma, Inc. possesses multiple third-party certifications of current Good Manufacturing Practice (cGMP) and Safe Quality Food (SQF) compliance from well-reputed organizations, such as Eurofins, NPA, NSF, and UL for supplement manufacturing in the United States.
Project Announcements
Ohio Lumex Expands Solon, Ohio, Operations
12/26/2025
Calgon Carbon Corporation Expands Pittsburgh, Pennsylvania, Operations
12/25/2025
Cascades Expands Eau Claire, Wisconsin, Operations
12/25/2025
P.C. Campana Plans Vicksburg, Mississippi, Production Operations
12/25/2025
Midwest Equipment Manufacturing Expands Maysville, Kentucky, Operations
12/25/2025
Stord Expands Hebron, Kentucky, Warehouse Operations
12/25/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025